依达拉奉联合尤瑞克林治疗急性脑梗塞的疗效观察

目的:观察依达拉奉联合尤瑞克林治疗急性脑梗塞的疗效及安全性。方法:将84例急性脑梗塞患者随机分为2组,对照组予依达拉奉30 mg加入生理盐水100 mL静脉滴注,每日两次。观察组在上述基础上另予尤瑞克林0.15 PNA加入生理盐水250mL中静脉滴注,每天一次。两组疗程均为2周。观察两组患者的神经功能缺损评分、疗效与不良反应。结果:两组患者神经功能缺损评分均较治疗前明显改善(P<0.01),观察组评分明显低于对照组(P<0.01)。观察组临床总有效率达97.6%,明显高于对照组的57.1%(P<0.01)。两组不良反应发生率无统计学差异。结论:达拉奉联合尤瑞克林治疗急性脑梗塞临床疗效好,安全性高。

Edaravone combined with urinary kallidinogenase for acute cerebral infarction

Objective: To observe the clinical effect and safety of combination therapy with edaravone and urinary kallidinogenase for acute cerebral infarction.Methods: 84 patients with acute cerebral infarction were randomly divided into 2 groups.Patients in control group were treated with 30 mg of edaravone in 100 mL of normal saline intravenously,twice daily.Based on the above treatment,patients in observation group were treated with 0.15 PNA of urinary kallidinogenase in 250 mL of normal saline intravenously,once ...